BUSINESS
SRF: Banking on the ramp-up of recently commissioned assets
The company’s margin improvement in the near term is contingent on its performance in the chemicals segment.
BUSINESS
This pharma stock gets the Budget tonic
The scrapping of customs duty will make cancer drugs of AstraZeneca affordable
BUSINESS
Sanstar IPO: Does this maize-based ingredients play make a worthy investment?
Near-term growth depends on upcoming expansion plan
BUSINESS
Himadri Speciality: Play on new energy transition
While there is still room for margin expansion for the legacy business, the stock is now more a play on the global energy transition which includes electric vehicles (EVs) and new-age battery systems
BUSINESS
Balaji Amines: Has the stock bottomed out?
The company has a significant surplus capacity, which can gain traction from the China-plus-one theme and a gradual global recovery. This should help in operating leverage over the years
BUSINESS
Indian equities: Will FII inflows get stronger with US rate cuts looking imminent?
US retail inflation is likely to cool down faster than expected as labour market is back in balance and excess savings have been exhausted
BUSINESS
US elections: What is in store for geopolitics and markets?
Equity markets have broadly performed well under both regimes historically
BUSINESS
FMCG: Can Budget 2024 help improve demand conditions?
Operating profit likely to be ahead of revenue growth
BUSINESS
Emcure IPO: Valuation stays too rich to pop the pill now
The company needs to recoup growth in the domestic business
BUSINESS
Why should one avoid fresh bets on Dr Reddy’s?
The Revlimid opportunity is transitional and its contribution to profitability is likely to reduce from CY27
BUSINESS
Fed meet: What does the hawkish dot plot imply for equities?
While in the recent past a few central banks such as the European Central Bank, Bank of Canada and the Swiss National Bank have embarked upon the rate easing cycle, inflation continues to be a spoilsport and hence requires a guarded watch.
BUSINESS
How should FIIs play as Modi 3.0 takes charge at the Centre?
For export-oriented sectors such as Auto and Chemicals, global growth is improving on a long-term perspective. However, one needs to be careful about short-term uncertainties in the interest rate trajectory. The other key watch for the medium term is the outcome of the US Presidential election and how it influences the China-plus-one trend.
BUSINESS
Syngene: The preferred pick for sector re-allocation
This strong CRAMS play can benefit from the easing funding crisis in the biotech industry, and the shift in global supply chains, in the post-pandemic world
BUSINESS
Which stocks are better placed to play the mass consumption theme?
FMCG sector, a preferred rural play, is on the cusp of a recovery
BUSINESS
Make-in-India and China-plus-one stocks plunge — Time to book profits or invest more?
Transforming the local manufacturing ecosystem will crucially hinge on the fresh policy push by the new government at the Centre
BUSINESS
Galaxy Surfactants: Volume growth visibility remains intact
As demand for specialty care products is expected to grow faster in FY25, the company’s profitability is likely to improve.
BUSINESS
Divi’s Lab: Custom synthesis business gaining ground
With custom synthesis scope widening and fresh opportunities in off-patented API molecules emerging, Divi’s is on a firm footing
BUSINESS
Sun Pharma: Time to book profit?
While the specialty pipeline is healthy and one of the drugs under review can potentially get launched in FY25, the growth outlook for FY25 appears dull
BUSINESS
Zydus Lifesciences: Why we still remain positive
Annual sales traction from Revlimid is decent and it is likely to stay so till 2026. The management is also positive about the product pipeline
BUSINESS
Navin Fluorine: Sequential pick-up, but recovery in CDMO biz a key lever
A Rs 288-crore capex for a new cGMP facility, supply agreement with Fermion, and the addition of a UK pharma major as a customer are among the new growth levers that keep the medium-term prospects bright for the CDMO segment.
BUSINESS
Ami Organics: Strong sequential uptick
As export demand is getting better, the company expects a steady growth in H1FY25 and guides for a stronger H2 on the back of CDMO business
BUSINESS
Cipla: Valuations cap upside unless peptide product launch picks up pace
The drug major posts moderate growth with lower operating margins
BUSINESS
SRF: Volume-led revival to accelerate in H2 FY25
The management believes that industry-wide challenges due to channel inventory and dumping by China are moderating and sees volume-led growth in the coming quarters.
BUSINESS
Dr Reddy’s: Watchful of the Revlimid cliff
In times to come, the company may gear up for new inorganic initiatives to improve its market share in India. In the meantime, margins may moderate
